

# Significant Differences in the Clinicopathological Characteristics and Survival of Gastric Cancer Patients from Two Cancer Centers in China and Korea

Zhan Long Shen\*, Kyo Young Song<sup>1\*</sup>, Ying Jiang Ye, Qi Wei Xie,  
Bin Liang, Kewei Jiang, Cho Hyun Park<sup>1\*\*</sup>, and Shan Wang\*\*

*Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing, China,  
<sup>1</sup>Department of Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea*

**Purpose:** To compare the clinicopathological data and long-term survival of gastric cancer patients in China and Korea.

**Materials and Methods:** Patients who had undergone gastrectomy for gastric cancer between 1998 and 2009 in 2 high-volume institutions in both China (n=1,637) and Korea (n=2,231) were retrospectively evaluated. Clinicopathological variables, overall survival (OS), progression-free survival (PFS), and surgery-related complications were assessed for all patients and compared between the 2 institutions.

**Results:** Chinese patients included in the study were significantly older and had a significantly lower body mass index (BMI) than the Korean patients. Esophagogastric junction tumors were more frequent in Chinese patients. However, the number of patients with stage I gastric cancer, the number of harvested lymph nodes, and the number of total gastrectomies were significantly higher in the Korean population. Korean patients also presented with fewer undifferentiated tumors than Chinese patients. Furthermore, Korean patients had prolonged OS and PFS for stage III cancers only. BMI, tumor-node-metastasis (TNM) stage, tumor invasion, number of positive lymph nodes, and distant metastases were all independent factors affecting OS and PFS.

**Conclusions:** Although China and Korea are neighboring Asian countries, the clinicopathological characteristics of Chinese patients are significantly different from those of Korean patients. Korean gastric cancer patients had longer OS and PFS than Chinese patients. Influencing factors included TNM stage, tumor invasion, and lymph node metastasis.

**Key Words:** Stomach neoplasms; Korea; China; Clinicopathological characteristics; Survival

Correspondence to: Cho Hyun Park

Department of Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea  
Tel: +82-2-2258-2876, Fax: +82-2-2258-2876

E-mail: [chpark@catholic.ac.kr](mailto:chpark@catholic.ac.kr)

Correspondence to: Shan Wang

Department of Gastroenterological Surgery, Peking University People's Hospital, No 11, Xizhimen South street, Xicheng District, Beijing 100044, China

Tel: +86-10-88326608, Fax : +86-10-88326608

E-mail: [shanwang60@sina.com](mailto:shanwang60@sina.com)

Received September 9, 2014

Revised November 28, 2014

Accepted December 1, 2014

\*These authors contributed equally to this paper as co-first authors.

\*\*These authors contributed equally to this paper as co-corresponding authors.

## Introduction

Gastric cancer is the third most common cause of cancer-related death worldwide.<sup>1</sup> The highest incidence rates are in East Asia, Eastern Europe, and South America.<sup>2-5</sup> Studies have shown that the clinicopathological presentation of gastric cancer, including histology, location, environmental exposure, and dietary factors, varies widely between Eastern and Western countries.<sup>6-8</sup> Moreover, the 5-year survival rate after curative gastrectomy for gastric cancer is lower in the West than in the East.<sup>9-11</sup> It is well known that many diseases in Korea and Japan share similar clinicopathological characteristics; these countries also have similar treatment policies and screening programs for gastric cancer, and achieve comparable

**Table 1. Pathological characteristics of gastric cancer patients**

| Variable                                  | China (n=1,637)  | Korea (n=2,231)  | P-value |
|---|------------------|------------------|---------|
| Gender                                    |                  |                  |         |
| Male                                      | 1,108 (67.7)     | 1,484 (66.5)     | 0.430   |
| Female                                    | 529 (32.3)       | 747 (33.5)       |         |
| Age (yr)                                  | 65 (17~93)       | 59 (18~91)       | <0.001* |
| BMI (kg/m <sup>2</sup> )                  | 21.9 (13.5~33.5) | 22.9 (13.7~35.9) | <0.001* |
| Family history of cancer                  |                  |                  | 0.322   |
| Yes                                       | 134 (8.2)        | 203 (8.1)        |         |
| No  | 1,503 (91.8)     | 2,028 (91.9)     |         |
| Family history of gastric cancer          | 71 (4.4)         | 104 (4.7)        | 0.328   |
| Location of tumor                         |                  |                  | <0.001* |
| EG junction                               | 90 (5.5)         | 12 (0.5)         |         |
| Upper                                     | 168 (10.3)       | 249 (11.2)       |         |
| Middle                                    | 326 (19.9)       | 800 (35.8)       |         |
| Lower                                     | 988 (60.3)       | 1,157 (51.9)     |         |
| Whole                                     | 65 (4.0)         | 13 (0.6)         |         |
| Differentiation                           |                  |                  | <0.001* |
| Differentiated                            | 431 (26.3)       | 1,015 (45.5)     |         |
| Undifferentiated                          | 1,206 (73.7)     | 1,216 (54.5)     |         |
| Tumor size (cm)                           | 5.5 (0.3~25.0)   | 3.5 (0.3~22.5)   | <0.001* |
| T-stage                                   |                  |                  | <0.001* |
| T1  | 197 (12.0)       | 1,222 (54.8)     |         |
| T2  | 234 (14.3)       | 557 (24.9)       |         |
| T3  | 515 (31.5)       | 402 (18.2)       |         |
| T4  | 691 (42.2)       | 50 (2.1)         |         |
| N-stage                                   |                  |                  | <0.001* |
| N0  | 489 (29.9)       | 1,420 (63.7)     |         |
| N1  | 241 (14.7)       | 294 (9.1)        |         |
| N2  | 354 (21.6)       | 204 (13.2)       |         |
| N3  | 553 (33.8)       | 313 (14.0)       |         |
| Stage                                     |                  |                  | <0.001* |
| I   | 260 (15.9)       | 1,436 (64.4)     |         |
| II  | 373 (22.8)       | 386 (17.3)       |         |
| III                                       | 896 (54.7)       | 348 (15.6)       |         |
| IV  | 108 (6.6)        | 61 (2.7)         |         |
| LN <sub>s</sub> harvested                 |                  |                  | <0.001* |
| Overall                                   | 19 (2~69)        | 39 (2~115)       | <0.001* |
| 0~14                                      | 311 (19.0)       | 57 (2.6)         | <0.001* |
| 15~20                                     | 743 (45.4)       | 134 (6.0)        | <0.001* |
| >20                                       | 583 (35.6)       | 2,040 (91.4)     | <0.001* |
| Lymph node status                         |                  |                  |         |
| Positive LN <sub>s</sub>                  | 6 (1~42)         | 4 (1~42)         | 0.655   |
| Positive LN <sub>s</sub> /total harvested | 0.22 (0~1)       | 0.12 (0~1)       | <0.001* |

Values are presented as number (%) or median (range). BMI = body mass index; EG = esophagogastric; LN = lymph node. \*P<0.05.

results.<sup>12-14</sup> In contrast, there are little data on the differences in the clinicopathological characteristics of gastric cancer between China and other Asian countries.<sup>15</sup>

The aim of this study was to compare the clinicopathological variables and outcomes between 2 high-volume gastric cancer centers in China and Korea. The goal of this work was to identify critical clinicopathological differences between Chinese and Korean patients and consequently improve treatment for gastric cancer patients.


## Materials and Methods

Patients diagnosed with gastric cancer and eligible for curative resection (R0) at either Peking University People's Hospital, China or Seoul St. Mary's Hospital, Korea between 1998 and 2009 were included in this study. We analyzed patient demographics, tumor factors, surgical factors, and survival. Patients who underwent R0 resection but who had no other history of cancer were included. Patients were excluded if they underwent neoadjuvant chemotherapy, wedge resection, or endoscopic mucosal resection. tumor-node-metastasis (TNM) classification was based on the 7th edition of the American Joint Committee on Cancer staging system. D1

or D1<sup>+</sup> lymphadenectomy was performed for early gastric cancer. D2 or D2<sup>+</sup> (D2+14v, or +12p, or +8p, or +16a) lymphadenectomy was performed for advanced cancer. The criteria for follow-up and recurrence were similar for both Korean and Chinese patients. Follow-up evaluation was repeated every 3 months for 2 years, every 6 months from the third to fifth post-operative year, and every year thereafter. The follow-up rates were 92.5% and 94.8% for Chinese patients and Korean patients, respectively.

## 1. Statistical analysis

The Statistical Package for the Social Sciences (SPSS) version 17.0 (SPSS Inc., Chicago, IL, USA) was used. The chi-square test was employed to assess differences in the categorical clinicopathological variables. The independent t-test was used to evaluate differences in continuous variables. Overall survival (OS) was calculated from the time of surgery to the last follow-up or date of death. For patients who experienced recurrence, progression-free survival (PFS) was calculated as the time from surgery to the time of first recurrence; for those with no recurrence, PFS was defined as the time from surgery to the last follow-up or death. Univariate survival analysis of OS and PFS was estimated using the Kaplan-Meier method. The Cox proportional hazards model



**Fig. 1.** Comparison of the overall survival (OS) of gastric cancer patients in both China and Korea. (A) Comparison of the OS of gastric cancer patients with all disease stages. (B) Comparison of the OS of stage I gastric cancer patients. (C) Comparison of the OS of stage II gastric cancer patients. (D) Comparison of the OS of stage III gastric cancer patients. (E) Comparison of the OS of stage IV gastric cancer patients. Cum = cumulative.

was used for multivariate analysis. Variables in the model included patient group, gender, age, body mass index (BMI), family history of cancer, operation type, digestive tract reconstruction methods, lymphadenectomy type, tumor location, tumor size, tumor differentiation, TNM stage, adjuvant chemotherapy, and number of harvested lymph nodes. P-values <0.05 were considered statistically significant.

## Results


### 1. Demographic data of gastric cancer patients

A total of 1,637 Chinese and 2,231 Korean gastric cancer pa-


tients were identified and compared. The age of the Chinese patients was significantly higher than that of the Korean patients ( $P < 0.001$ ). The BMI of the Chinese patients was significantly lower than that of the Korean patients ( $P < 0.001$ ). There was no significant difference in family history of any type of cancer, including gastric cancer, between the 2 institutions (Table 1).

### 2. Surgical characteristics of gastric cancer patients

Korean surgeons performed significantly more total gastrectomies, multivisceral resections, and Billroth II digestive tract reconstructions compared with their Chinese counterparts, and less postoperative chemotherapy was administered in Korea ( $P < 0.001$ ;



**Fig. 2.** Comparison of the overall survival (OS) of gastric cancer patients with different T and N stages in both China and Korea. (A) Comparison of the OS of stage T1 gastric cancer patients. (B) Comparison of the OS of stage T2 gastric cancer patients. (C) Comparison of the OS of stage T3 gastric cancer patients. (D) Comparison of the OS of stage T4 gastric cancer patients. (E) Comparison of the OS of stage N0 gastric cancer patients. (F) Comparison of the OS of stage N1 gastric cancer patients. (G) Comparison of the OS of stage N2 gastric cancer patients. (H) Comparison of the OS of stage N3 gastric cancer patients. Cum = cumulative.



**Fig. 3.** Comparison of the progression-free survival (PFS) of gastric cancer patients in both China and Korea. (A) Comparison of the PFS of gastric cancer patients with all disease stages. (B) Comparison of the PFS of stage I gastric cancer patients. (C) Comparison of the PFS of stage II gastric cancer patients. (D) Comparison of the PFS of stage III gastric cancer patients. (E) Comparison of PFS of stage IV gastric cancer patients. Cum = cumulative.

Supplementary Table 1). D2<sup>+</sup> lymphadenectomy was performed in 79% of advanced cases in Korea (797/1,009), but was not performed in any of the Chinese cases in this study (0/1,440).

There were no significant differences in the incidence of major surgery-related complications between the 2 institutions ( $P=0.42$ ). These complications included anastomotic leakage, anastomotic stenosis, intra-abdominal bleeding, postoperative ileus, and postoperative intra-abdominal infection (Supplementary Table 2).

### 3. Pathological characteristics of gastric cancer patients

Chinese gastric cancer patients had more tumors located in the esophagogastric (EG) junction and whole stomach ( $P<0.001$ ), and a greater number of undifferentiated tumors ( $P<0.001$ ) compared with Korean patients. Tumors in Chinese patients were generally larger than those in Korean patients ( $P<0.001$ ).

There were more gastric cancer patients with relatively early-stage disease including T1, T2, N0, and stage I, in Korea than in China ( $P<0.001$ ).

More lymph nodes were harvested from Korean patients than from Chinese patients ( $P<0.001$ ). The ratio of positive lymph

nodes to total nodes examined was significantly higher in China than in Korea ( $P<0.001$ ; Table 1).


## 4. Survival analysis

### 1) Overall survival

The OS of Korean patients was longer than that of Chinese patients ( $P<0.001$ ), especially for stage III disease ( $P<0.001$ ). Analysis based on T and N stages showed that the OS for Korean patients with stages T3 ( $P=0.011$ ) and T4 ( $P=0.036$ ) or N2 ( $P=0.002$ ) and N3 ( $P<0.001$ ), but not T1 ( $P=0.299$ ) and T2 ( $P=0.085$ ) or N0 ( $P=0.062$ ) and N1 ( $P=0.090$ ), was significantly longer than that of Chinese patients with an equivalent disease stage (Fig. 1, 2).

### 2) Progression-free survival

Korean patients with either stage III ( $P<0.001$ ) or stage IV ( $P=0.106$ ), but not stage I or II disease, had a longer PFS than Chinese patients with the same disease stage. Korean patients with stages T3 ( $P=0.001$ ), T4 ( $P=0.002$ ), N2 ( $P<0.001$ ), or N3 ( $P<0.001$ ), but not T1 ( $P=0.726$ ), T2 ( $P=0.075$ ), N0 ( $P=0.226$ ), or N1 ( $P=0.485$ ), had a significantly longer PFS than Chinese patients (Fig. 3, 4).



**Fig. 4.** Comparison of the progression-free survival (PFS) of gastric cancer patients with different T and N stages in both China and Korea. (A) Comparison of the PFS of stage T1 gastric cancer patients. (B) Comparison of the PFS of stage T2 gastric cancer patients. (C) Comparison of the PFS of stage T3 gastric cancer patients. (D) Comparison of the PFS of stage T4 gastric cancer patients. (E) Comparison of the PFS of stage N0 gastric cancer patients. (F) Comparison of the PFS of stage N1 gastric cancer patients. (G) Comparison of the PFS of stage N2 gastric cancer patients. (H) Comparison of the PFS of stage N3 gastric cancer patients. Cum = cumulative.

### 3) Independent factors affecting overall survival and progression-free survival

The Cox proportional hazards model showed that patient group, age, and TNM stage were independent risk factors affecting both OS and PFS, whereas BMI was an independent risk factor for OS but not PFS (Supplementary Table 3).

## Discussion

To date, there has been little research comparing the different gastric cancer characteristics in Korea and China. Our study

showed that Chinese patients were older than Korean patients and had lower BMI values. These findings can be partly explained by the nationwide screening system that was introduced in Korea in 1999 as part of the National Cancer Screening Program,<sup>16-18</sup> which ensured early cancer detection.<sup>19-21</sup>

Korean and Chinese institutions have different surgical policies.<sup>22</sup> Our data showed that Korean surgeons performed more total gastrectomies for tumors located in the proximal part of the stomach than their Chinese counterparts. They also preferred extensive surgery for T4 gastric cancer, in contrast to most Chinese surgeons who follow the National Comprehensive Cancer Network guide-

lines and prefer pre-operative chemotherapy followed by radical resection of the tumor for these patients.

Interestingly, our results showed that the rate of EG junction cancer was significantly higher in Chinese than in Korean patients. Patients in Western countries have more EG junction tumors than those in Asian countries.<sup>23</sup> Data from the Memorial Sloan-Kettering Cancer Center<sup>8</sup> showed that 18% of all gastric cancers were located at the EG Junction. In this study, we found that Chinese patients had significantly more EG junction tumors than Korean patients, but fewer EG junction tumors than those in the US.<sup>24</sup> Although both China and Korea are in Asia, the countries have very different diets, which may contribute to clinicopathological differences. Chinese food is typically oily and resembles a Western-style diet.

Korean patients with advanced-stage cancer had longer OS and PFS compared to Chinese patients. We hypothesized that this difference might be due to different treatment policies, while the longer OS of Korean patients might be partially related to their younger age. Korean surgeons traditionally prefer extended surgery, especially D2<sup>+</sup> lymphadenectomy, for advanced gastric cancer. D2<sup>+</sup> lymphadenectomy was performed in 79% of advanced cases in Korea, but was not performed in any of the Chinese cases in this study. However, the overall percentage of D2<sup>+</sup> lymphadenectomies was lower in Korean patients due to the lower ratio of advanced gastric cancer in this group. In fact, the benefit of extended D2 lymphadenectomy for gastric cancer remains unclear, although some studies have proposed its use.<sup>25-27</sup> However, other researchers have contrasting opinions.<sup>28-30</sup> While the number of lymph nodes harvested in Korean patients was significantly greater than that in Chinese patients, multivariate analysis showed that this was not an independent risk factor affecting OS and PFS. Therefore, we speculated that the number of lymph nodes harvested and extent of lymphadenectomy might be important for the survival of gastric cancer patients, especially those with non-metastatic advanced gastric cancers such as stage III; however, it is probably irrelevant for early stage (stage I, II) and metastatic cancers (stage IV). Moreover, the poorer survival of Chinese patients, particularly those with stage III disease, might also be partially attributed to downstaging<sup>31</sup> because of the insufficient number of lymph nodes harvested (approximately 20% of patients had < 15 lymph nodes harvested).

The number of lymph nodes harvested is dependent on both surgical technique and the pathologist's experience. A multidisciplinary team (MDT) could improve communication between surgeons and pathologists, and ensure that the lymph nodes are

checked by pathologists.<sup>32</sup> In this study, a MDT was established in the Chinese institution in 2010. For patients with fewer than 15 lymph nodes harvested, accurate staging might be accomplished by dividing by the metastatic lymph node ratio,<sup>33</sup> referred to in the TNM staging system, but more evidence is needed to support this strategy.

In summary, we find that some clinicopathological variables are different between Korean and Chinese gastric cancer patients. Korean gastric cancer patients have longer OS and PFS compared to Chinese patients with advanced disease stages. This study may guide the future direction of gastric cancer research in both China and Korea, and may provide evidence to influence surgical treatment policies in both countries.

## References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. *Eratum: global cancer statistics. CA Cancer J Clin* 2011;61:134.
2. Parkin DM. *The global health burden of infection-associated cancers in the year 2002. Int J Cancer* 2006;118:3030-3044.
3. Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, et al. *Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut* 2006;55:1545-1552.
4. Shin A, Kim J, Park S. *Gastric cancer epidemiology in Korea. J Gastric Cancer* 2011;11:135-140.
5. Yang L. *Incidence and mortality of gastric cancer in China. World J Gastroenterol* 2006;12:17-20.
6. Schwarz RE, Zagala-Nevarez K. *Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur J Surg Oncol* 2002;28:214-219.
7. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, et al. *Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer* 2002;5:208-212.
8. Bickenbach K, Strong VE. *Comparisons of gastric cancer treatments: East vs. West. J Gastric Cancer* 2012;12:55-62.
9. Karpeh MS, Leon L, Klimstra D, Brennan MF. *Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg* 2000;232:362-371.
10. Theuer CP. *Asian gastric cancer patients at a southern California comprehensive cancer center are diagnosed with less advanced disease and have superior stage-stratified survival. Am*

- Surg 2000;66:821-826.
11. Katanoda K, Matsuda T, Matsuda A, Shibata A, Nishino Y, Fujita M, et al. An updated report of the trends in cancer incidence and mortality in Japan. *Jpn J Clin Oncol* 2013;43:492-507.
  12. Mok YJ, Koo BW, Whang CW, Kim SM, Maruyama K, Sasako M, et al. Cancer of the stomach: a review of two hospitals in Korea and Japan. *World J Surg* 1993;17:777-782.
  13. Nakajima S. Gastric cancer screening in Japan, now and tomorrow. *Nihon Rinsho* 2012;70:1686-1693.
  14. Tokunaga M, Sano T, Ohyama S, Hiki N, Fukunaga T, Yamada K, et al. Clinicopathological characteristics and survival difference between gastric stump carcinoma and primary upper third gastric cancer. *J Gastrointest Surg* 2013;17:313-318.
  15. Yu M, Zheng HC, Xia P, Takahashi H, Masuda S, Takano Y, et al. Comparison in pathological behaviours & prognosis of gastric cancers from general hospitals between China & Japan. *Indian J Med Res* 2010;132:295-302.
  16. Yoo KY. Cancer control activities in the Republic of Korea. *Jpn J Clin Oncol* 2008;38:327-333.
  17. Kim Y, Jun JK, Choi KS, Lee HY, Park EC. Overview of the National Cancer screening programme and the cancer screening status in Korea. *Asian Pac J Cancer Prev* 2011;12:725-730.
  18. Choi KS, Jun JK, Lee HY, Park S, Jung KW, Han MA, et al. Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea. *Cancer Sci* 2011;102:1559-1564.
  19. Donaldson MS. Nutrition and cancer: a review of the evidence for an anti-cancer diet. *Nutr J* 2004;3:19.
  20. Divisi D, Di Tommaso S, Salvemini S, Garramone M, Crisci R. Diet and cancer. *Acta Biomed* 2006;77:118-123.
  21. Gonzalez CA. Nutrition and cancer: the current epidemiological evidence. *Br J Nutr* 2006;96 Suppl 1:S42-S45.
  22. Park CH, Song KY, Kim SN. Treatment results for gastric cancer surgery: 12 years' experience at a single institute in Korea. *Eur J Surg Oncol* 2008;34:36-41.
  23. Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. *World J Surg* 2009;33:95-103.
  24. Chung JW, Lee GH, Choi KS, Kim DH, Jung KW, Song HJ, et al. Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification. *Dis Esophagus* 2009;22:676-681.
  25. Deng J, Liang H, Sun D, Pan Y, Liu Y, Wang D. Extended lymphadenectomy improvement of overall survival of gastric cancer patients with perigastric node metastasis. *Langenbecks Arch Surg* 2011;396:615-623.
  26. Kosaka T, Usami K, Ueshige N, Hasegawa T, Yoshitani S, Sugaya J, et al. Paraaortic lymph node dissection for gastric cancer in 244 consecutive cases. *Hepatogastroenterology* 2006;53:629-633.
  27. Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, et al. A prospective pilot study of extended (D3) and super-extended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. *Surgery* 1999;125:325-331.
  28. Hu JK, Yang K, Zhang B, Chen XZ, Chen ZX, Chen JP. D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery. *Surg Today* 2009;39:207-213.
  29. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008;359:453-462.
  30. An JY, Pak KH, Inaba K, Cheong JH, Hyung WJ, Noh SH. Relevance of lymph node metastasis along the superior mesenteric vein in gastric cancer. *Br J Surg* 2011;98:667-672.
  31. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. *Ann Surg Oncol* 2007;14:317-328.
  32. Chen S, Zhao BW, Li YF, Feng XY, Sun XW, Li W, et al. The prognostic value of harvested lymph nodes and the metastatic lymph node ratio for gastric cancer patients: results of a study of 1,101 patients. *PLoS One* 2012;7:e49424.
  33. Lee SR, Kim HO, Son BH, Shin JH, Yoo CH. Prognostic significance of the metastatic lymph node ratio in patients with gastric cancer. *World J Surg* 2012;36:1096-1101.



**Supplementary Table 1. Surgical characteristics of gastric cancer patients**

| Characteristic                      | China (n=1,637) | Korea (n=2,231) | P-value |
|-------------------------------------|-----------------|-----------------|---------|
| Operation                           |                 |                 | <0.001* |
| Total gastrectomy                   | 183 (11.1)      | 654 (29.4)      |         |
| Distal subtotal gastrectomy         | 1,245 (76.1)    | 1,577 (70.6)    |         |
| Proximal gastrectomy                | 209 (12.8)      | 0 (0.0)         |         |
| Multivisceral combined resection    | 51 (3.1)        | 183 (8.2)       |         |
| Reconstruction of digestive tract   |                 |                 | <0.001* |
| Billroth I                          | 497 (30.4)      | 218 (9.8)       |         |
| Billroth II                         | 723 (44.2)      | 1,302 (58.4)    |         |
| Roux-en-Y (Stomach-Jejunum)         | 25 (1.5)        | 57 (2.6)        |         |
| Roux-en-Y (Esophagus-Jejunum)       | 183 (11.2)      | 654 (29.2)      |         |
| Esophagogastrostomy                 | 209 (12.7)      | 0 (0.0)         |         |
| Lymphadenectomy                     |                 |                 | <0.001* |
| <D2                                 | 223 (13.6)      | 643 (28.8)      |         |
| ≥D2                                 | 1,414 (86.4)    | 1,588 (71.2)    |         |
| Surgery-related major complications | 96 (5.8)        | 133 (6.0)       | 0.899   |
| Postoperative chemotherapy          | 975 (59.6)      | 864 (38.7)      | <0.001* |

Values are presented as number (%). \*P<0.05.

**Supplementary Table 2. Major surgery-related complications**

| Major surgery-related complications | China (n=1,637) | Korea (n=2,231) |
|-------------------------------------|-----------------|-----------------|
| Anastomotic leakage                 | 15 (0.9)        | 35 (1.6)        |
| Anastomotic stenosis                | 24 (1.5)        | 20 (0.9)        |
| Intra-abdominal bleeding            | 12 (0.7)        | 13 (0.6)        |
| Postoperative ileus                 | 34 (2.1)        | 52 (2.3)        |
| Intra-abdominal infection           | 10 (0.6)        | 13 (0.6)        |
| Total cases                         | 95 (5.8)        | 133 (6.0)       |

Values are presented as number (%).

Supplementary Table 3. Cox proportional hazards model for OS and PFS

| Variable                          | OS      |       |               | DFS     |       |               |
|-----------------------------------|---------|-------|---------------|---------|-------|---------------|
|                                   | P-value | HR    | 95% CI for HR | P-value | HR    | 95% CI for HR |
| Group                             | 0.001*  | 2.006 | 1.337~3.010   | 0.003*  | 1.775 | 1.220~2.582   |
| Age                               | 0.041*  | 1.012 | 1.000~1.024   | 0.012*  | 1.015 | 1.003~1.026   |
| TNM stage                         | <0.001* | 2.948 | 2.440~3.562   | <0.001* | 2.819 | 2.359~3.368   |
| BMI                               | 0.021*  | 0.964 | 0.934~0.995   | 0.069   | 0.972 | 0.942~1.002   |
| Family history of cancer          | 0.221   | 0.471 | 0.141~1.573   | 0.123   | 0.383 | 0.113~1.295   |
| Operation type                    | 0.869   | 0.983 | 0.800~1.207   | 0.768   | 0.971 | 0.800~1.179   |
| Reconstruction of digestive tract | 0.881   | 1.011 | 0.879~1.163   | 0.813   | 1.016 | 0.888~1.164   |
| Tumor location                    | 0.604   | 0.953 | 0.793~1.144   | 0.442   | 0.933 | 0.782~1.113   |
| Tumor size                        | 0.713   | 0.990 | 0.940~1.043   | 0.702   | 1.010 | 0.962~1.060   |
| Postoperative chemotherapy        | 0.509   | 1.129 | 0.787~1.620   | 0.583   | 1.102 | 0.779~1.558   |
| Differentiation                   | 0.742   | 0.947 | 0.685~1.309   | 0.602   | 0.923 | 0.683~1.247   |
| Lymph nodes harvested             | 0.287   | 0.994 | 0.982~1.005   | 0.181   | 0.992 | 0.981~1.004   |

OS = overall survival; PFS = progression-free survival; CI = confidence interval; HR = hazard ratio; TNM = tumor-node-metastasis; BMI = body mass index. \*P<0.05. Reference variables: group, Korean patients; age, younger patients; TNM stage, stage I; BMI, lower BMI; family history of cancer, positive family history of cancer; operation type, distal gastrectomy; reconstruction of digestive tract, Billroth I; tumor location, EJ junction; tumor size, smaller; postoperative chemotherapy, without chemotherapy; differentiation, undifferentiated; lymph nodes harvested, low harvest.